DK323587D0 - Protein - Google Patents

Protein

Info

Publication number
DK323587D0
DK323587D0 DK323587A DK323587A DK323587D0 DK 323587 D0 DK323587 D0 DK 323587D0 DK 323587 A DK323587 A DK 323587A DK 323587 A DK323587 A DK 323587A DK 323587 D0 DK323587 D0 DK 323587D0
Authority
DK
Denmark
Prior art keywords
proteolytically
viia
factor vii
sensible
stabilization
Prior art date
Application number
DK323587A
Other languages
English (en)
Inventor
Soeren Erik Bjoern
Else Marie Nicolaisen
Finn Christoph Wiberg
Richard Woodbury
Original Assignee
Novo Industri As
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Industri As, Zymogenetics Inc filed Critical Novo Industri As
Priority to DK323587A priority Critical patent/DK323587D0/da
Publication of DK323587D0 publication Critical patent/DK323587D0/da
Priority to NO874548A priority patent/NO172235C/no
Priority to EP88905735A priority patent/EP0370036B1/en
Priority to JP63505496A priority patent/JPH03500963A/ja
Priority to AT88905735T priority patent/ATE76900T1/de
Priority to DE8888905735T priority patent/DE3871798T2/de
Priority to PCT/DK1988/000103 priority patent/WO1988010295A1/en
Priority to CA000570535A priority patent/CA1339815C/en
Priority to DK653989A priority patent/DK161097C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK323587A 1986-11-03 1987-06-25 Protein DK323587D0 (da)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DK323587A DK323587D0 (da) 1987-06-25 1987-06-25 Protein
NO874548A NO172235C (no) 1986-11-03 1987-11-02 Analogifremgangsmaate for fremstilling av terapeutisk aktive piperidinforbindelser
EP88905735A EP0370036B1 (en) 1987-06-25 1988-06-24 Modified factor vii/viia
JP63505496A JPH03500963A (ja) 1987-06-25 1988-06-24 変更７／７ａ因子
AT88905735T ATE76900T1 (de) 1987-06-25 1988-06-24 Modifizierter faktor vii/viia.
DE8888905735T DE3871798T2 (de) 1987-06-25 1988-06-24 Modifizierter faktor vii/viia.
PCT/DK1988/000103 WO1988010295A1 (en) 1987-06-25 1988-06-24 MODIFIED FACTOR VII/VIIa
CA000570535A CA1339815C (en) 1987-06-25 1988-06-27 Modified factor vii/viia
DK653989A DK161097C (da) 1987-06-25 1989-12-21 Modificeret faktor vii/viia, dna-sekvens, som koder herfor, ekspressionsvektor indeholdende en saadan dna-sekvens, celle, der er transformeret med en saadan vektor og fremgangsmaade til fremstilling af modificeret faktor vii/viia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK323587A DK323587D0 (da) 1987-06-25 1987-06-25 Protein

Publications (1)

Publication Number Publication Date
DK323587D0 true DK323587D0 (da) 1987-06-25

Family

ID=8120606

Family Applications (2)

Application Number Title Priority Date Filing Date
DK323587A DK323587D0 (da) 1986-11-03 1987-06-25 Protein
DK653989A DK161097C (da) 1987-06-25 1989-12-21 Modificeret faktor vii/viia, dna-sekvens, som koder herfor, ekspressionsvektor indeholdende en saadan dna-sekvens, celle, der er transformeret med en saadan vektor og fremgangsmaade til fremstilling af modificeret faktor vii/viia

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK653989A DK161097C (da) 1987-06-25 1989-12-21 Modificeret faktor vii/viia, dna-sekvens, som koder herfor, ekspressionsvektor indeholdende en saadan dna-sekvens, celle, der er transformeret med en saadan vektor og fremgangsmaade til fremstilling af modificeret faktor vii/viia

Country Status (7)

Country Link
EP (1) EP0370036B1 (da)
JP (1) JPH03500963A (da)
AT (1) ATE76900T1 (da)
CA (1) CA1339815C (da)
DE (1) DE3871798T2 (da)
DK (2) DK323587D0 (da)
WO (1) WO1988010295A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
ES2113878T3 (es) * 1989-12-29 1998-05-16 Zymogenetics Inc Proteina c hibrida.
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
CA2074839C (en) * 1990-01-29 2000-11-14 Kathleen L. Berkner Modified factor vii anticoagulant proteins
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
PL204285B1 (pl) 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
IL154520A0 (en) * 2000-09-13 2003-09-17 Novo Nordisk As Human coagulation factor vii variants
CZ2003611A3 (cs) * 2000-09-13 2003-08-13 Novo Nordisk A/S Varianty lidského koagulačního faktoru VII
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
CZ20032454A3 (en) * 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
ES2376694T3 (es) * 2001-09-27 2012-03-16 Novo Nordisk Health Care Ag Polipã‰ptidos del factor vii de coagulaciã“n humano.
AU2002336919A1 (en) * 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
BR0309576A (pt) 2002-04-30 2005-02-09 Maxygen Holdings Ltd Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
CA2502162C (en) 2002-09-30 2014-04-15 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
AU2004221761B2 (en) 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
DE602004025576D1 (de) 2003-06-19 2010-04-01 Bayer Healthcare Llc Varianten der faktor-vii- oder -viia-gla-domäne
ATE547519T1 (de) * 2003-09-09 2012-03-15 Novo Nordisk Healthcare Ag Gerinnungsfaktor-vii-polypeptide
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
MX2007001294A (es) 2004-08-17 2008-03-04 Zlb Behring Gmbh Polipeptidos modificados que dependen de vitamina k.
WO2008127702A2 (en) 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypetides and uses thereof
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
FR2917414B1 (fr) * 2007-06-15 2012-07-13 Lab Francais Du Fractionnement Facteur vii/viia humain modifie et composition pharmaceutique contenant celui-ci
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
ES2966234T3 (es) 2009-06-09 2024-04-18 Prolong Pharmaceuticals Llc Composiciones de hemoglobina
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2461040A1 (fr) * 1979-07-09 1981-01-30 Inst Textile De France Procede et dispositif pour l'obtention d'un fil presentant sur sa longueur des zones de torsion alternativement de sens inverse
US4753879A (en) * 1984-08-27 1988-06-28 Biogen N.V. Modified tissue plasminogen activators
EP0201153A3 (en) * 1985-02-09 1987-10-07 Beecham Group Plc Modified enzyme and process for its preparation
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
DK43387A (da) * 1986-01-29 1987-07-30 Beecham Group Plc Fibrinolytisk enzym

Also Published As

Publication number Publication date
DK161097B (da) 1991-05-27
DK653989A (da) 1989-12-21
EP0370036A1 (en) 1990-05-30
JPH03500963A (ja) 1991-03-07
DE3871798T2 (de) 1993-05-13
ATE76900T1 (de) 1992-06-15
WO1988010295A1 (en) 1988-12-29
DE3871798D1 (de) 1992-07-09
EP0370036B1 (en) 1992-06-03
DK653989D0 (da) 1989-12-21
CA1339815C (en) 1998-04-14
DK161097C (da) 1991-11-11

Similar Documents

Publication Publication Date Title
DK323587D0 (da) Protein
DK105489D0 (da) Polypeptid
DE69129865D1 (de) Osteogene peptide
KR880701105A (ko) 신규 응혈촉진 단백질
ATE80166T1 (de) Verfahren zur isolierung rekombinanter polypeptide in biologisch aktiver form.
DE3856265D1 (de) Varianten des pankreatischen Rinder-Trypsininhibitors, deren Herstellung und Verwendung
LU90458I2 (fr) Refacto
DE69839812D1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
ES8802235A1 (es) Procedimiento para preparar un polipeptido
HUT54213A (en) Process for the enzymatic removal of n-terminal sequence of proteins
ES2112255T3 (es) Complejos proteicos que tienen actividad del factor viii:c y su produccion.
ATE144535T1 (de) Plättchen blockierende peptide
ATE339878T1 (de) Myc-bindende zinkfinger-proteine, ihre herstellung und ihre verwendung
BR9809416A (pt) Processo para clivagem de proteìnas de fusão
MX9203879A (es) Muteina de il-6 con cisteina parcialmente suprimida.
ES2168282T3 (es) D-hidantoinasa recombinante, procedimiento para su preparacion y utilizacion.
ATE163045T1 (de) Somatotropine des schweines mit modifikationen im bereich der alpha helix 1 und kombinationen mit anderen mutationen
DK262986D0 (da) Peptidmateriale med thymushumoral aktivitet
DE3873273D1 (de) Verfahren zur selektiven spaltung von fusionsproteinen.
FR2569111B1 (fr) Nouveaux medicaments contenant des tripeptides
FI942392A0 (fi) Peptidejä ja vasta-aineita nivelreuman hoitoon
DE69121489D1 (de) In vitro-Behandlung von Fusionsproteinen
AU637589B2 (en) Ancrod proteins, their production and use
AU665935B2 (en) Thrombolytic peptide, production thereof and thrombolytic agent
ATE106944T1 (de) Rekombinante polypeptide des hämorrhagischen fisch-sepsis-virus.

Legal Events

Date Code Title Description
ATS Application withdrawn